Lineage Cell Therapeutics

Yahoo Finance • 19 days ago

Lineage Cell Therapeutics, Inc. (LCTX) Shows Vision Gains in Phase 1/2a OpRegen Trial

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Lineage Cell Therapeutics, Inc. is one of them. Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is a clinical-stage biotech company developi... Full story

Yahoo Finance • 2 months ago

Lineage Cell Revenue Doubles in Q2

Key Points GAAP revenue doubled in Q2 2025 compared to Q2 2024, significantly beating analyst expectations on a GAAP basis as Collaboration income (GAAP) also doubled compared to Q2 2024. Net loss (GAAP) increased sharply due to large non... Full story

Yahoo Finance • 2 months ago

Lineage signals expanded diversification strategy following OpRegen milestones and $42.3M cash position

Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q2 2025 MANAGEMENT VIEW * CEO Brian M. Culley highlighted sustained progress for OpRegen, noting "the anatomical and functional benefits, which we first reported have lasted for... Full story

Yahoo Finance • 2 months ago

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Successfully Reduced-to-Practice Critical Aspect of Commercial-Scale, Cell-Based, GMP Production Processes First Chronic P... Full story

Yahoo Finance • 4 months ago

OpRegen ® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion siteEvidence of retinal structural improvement persisted out to 3 yearsAnatomical and functional improveme... Full story

Yahoo Finance • 2 years ago

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2023 Earnings Call Transcript

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2023 Earnings Call Transcript May 11, 2023 Lineage Cell Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.03 EPS, expectations were $-0.02478. Operator: Welcome to the... Full story

Yahoo Finance • 3 years ago

Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer

CARLSBAD, Calif., October 31, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that... Full story

Yahoo Finance • 3 years ago

Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Advanced RG6501 (OpRegen®) Development in Partnership with Roche and Genentech Published OPC1 Phase 1/2a Clinical Study Results in Journal of Neurosurgery: Spine Completed Key Activities to Support Planned Regulatory Interactions for OPC1... Full story

Yahoo Finance • 3 years ago

Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Reported RG6501 (OpRegen®) Clinical Results at 2022 ARVO Meeting; Outer Retinal Structure Improvement Observed in Five Dry AMD Patients Expanded Pipeline with Two New Cell Therapy Development Programs; Auditory Neurons and Photoreceptors A... Full story

Yahoo Finance • 3 years ago

Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022

Fireside Chat with B. Riley Research Analyst Scheduled for 3:30pm Eastern Time Topics Will Include Two New Cell Therapy Programs Launched Following Roche and Genentech Partnership for RG6501 (OpRegen®) Program CARLSBAD, Calif., April 26,... Full story

Yahoo Finance • 4 years ago

Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer

CARLSBAD, Calif., April 13, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Ca... Full story